Marie Jarbath
Surgical · Webster, TXNPI 1164425195
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,726 of the $10,363 with a category attached, or 84.2%. It is spread thinly across 44 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,422 and has fallen 53.7% since, to $1,583 in 2025. Among surgical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $34.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$2K
- Tersera Therapeutics LLC$1K
- Nevro Corp.$1K
- Boston Scientific$754
- Collegium Pharmaceutical, Inc.$723
- Medtronic$693
- plus $4K from 38 others
What the payments were for
- Travel & lodging$1,59215%
- Food & beverage$8,72684%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke$1,582
- Intracept$644
- SYNCHROMEDII$326
- Omnia$312
- Senza$261
- Inspire$246
- BIOTRONIK$140
- SPRINT PNS System$135
- mild Device Kit$130
- BELBUCA$109
- Symproic$109
How this compares
$10,363 in reported general payments places this provider in the 95th percentile of 804 surgical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 70 | $47,085 |
| Buprenorphine | 64 | $14,936 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 366 | $7,090 |
| Tramadol Hcl | 551 | $6,053 |
| Tramadol Hcl ErTramadol Hcl | 98 | $4,773 |
| Pregabalin | 175 | $3,567 |
| Gabapentin | 119 | $1,809 |
| Cyclobenzaprine Hcl | 97 | $1,151 |
| Tizanidine Hcl | 53 | $572 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 43 | $569 |
| Duloxetine Hcl | 51 | $563 |
| Baclofen | 34 | $425 |
| Celecoxib | 37 | $419 |
| Methocarbamol | 38 | $379 |
| Carisoprodol | 30 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $723 | $47,08570 claims |
| Hikma Pharmaceuticals USABuprenorphine | $19 | $14,93664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 surgical providers in Texas.
Other surgical in Webster
- Courtney DunavantAustin$389K
- Krista GranthamSan Antonio$187K
- Gerald BuchertBellaire$148K
- Gilberto SaenzGeorgetown$70K
- Andrea McNielHumble$48K
- Marilyn ShookHouston$46K
- Henry KinnebrewAustin$40K
- Josephine KarlDallas$18K
- Sarah IragorriAustin$18K
- Lonnie GinnDallas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.